Abstract
This study reports the reliability and validity of the Brazilian Portuguese version of QLQ-LC13. After translation and cross-cultural adaptation, the questionnaire was administered, together with the QLQ-C30 core questionnaire, to 82 patients with lung cancer. The analysis was based on 60 patients who completed two interviews, and who received chemotherapy alone or in combination with radiotherapy. The reliability or internal consistency of dyspnea scale was 0.79. The pain scale needed to be combined with the QLQ-C30 pain items to reach a satisfactory value of 0.73. The construct validity was supported by the ability of the questionnaire to discriminate patients regarding their performance status and type of treatment. However, the change over time, although in the expected direction for all items, was statistically significant in four of the 10 items studied. The criterion-related validity was supported by the statistically significant correlation between all four side effect items and the physicians’ reports of toxicity, while the evolutive changes in the performance status were statistically significant in only four items. Most psychometric properties of the Brazilian version of the QLQ-LC13 were adequately supported in this analysis. However, a wider utilization of this module is necessary to fully ascertain its reliability and validity properties.
This is a preview of subscription content, log in via an institution to check access.
References
Brasil. Ministério da Saúde. Secretaria Nacional de Assistência à Saúde. Instituto Nacional de Câncer. Atlas de Mortalidade por Câncer no Brasil 1979–1999. Rio de Janeiro: INCA 2002
Schiller JH, Harrington D, Belani CP (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98
Fallowfield LJ, Harper P (2005) Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 48:365–377
EORTC Quality of Life Group website: http://www.eortc.be/home/qol/
Aaronson K, Ahmedzai S, Bergman B, et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
Bergman B, Aaronson NK, Ahmedzai S, et al (1994) The EORTC QLQLC-13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635–42
Cull A, Sprangers M, Bjordal K. EORTC Quality of Life Study Group Translation Procedure. 2nd ed., 2002
National Cancer Institute – Cancer Therapy Evaluation Program – Common Toxicity Criteria Manual, version 2.0. June 1, 1999
Lung Cancer Module: QLQ-LC13. In EORTC Quality of Life Group. EORTC QLQ-C30 Scoring Manual. 2nd ed., 1999
Nunnally JC, Bernstein IR. Psychometric Theory, 3rd ed., New York: Mcgraw-Hill, 1994
Flesch RF (1948) A new readability yardstick. J Appl Psychol 32:221–233
Brasil. Ministério da educação. Sistema nacional de avaliação da educação básica. Qualidade da educação: Uma nova leitura do desempenho dos estudantes da oitava série do ensino fundamental. Brasília, 2003
Weinberger M, Oddone EZ, Samsa GP (1996) Are heath-related quality of life measures affected by the mode of administration? J Clin Epidemiol 49:135–140
Acknowledgements
The authors wish to thank Ms. Karen West, from the Quality of Life Unit of the EORTC, for assistance throughout the translation and cultural adaptation phases of the study. We are also grateful to the staffs of “Cetho” and “Oncoclínica” for their kind cooperation.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Brazilian Version of QLQ-LC13
EORTC QLQ-LC13
EORTC QLQ-LC13Por vezes, os pacientes se queixam da ocorrência dos seguintes sintomas. Por favor, indique até que ponto sentiu esses sintomas ou problemas na semana passada, fazendo um círculo em volta do número que melhor se aplica a você.
Durante a semana passada: | |||||
|---|---|---|---|---|---|
Não | Pouco | Modera damente | Muito | ||
1. Quanto tossiu? | 1 | 2 | 3 | 4 | |
2. Tossiu sangue? | 1 | 2 | 3 | 4 | |
3. Sentiu falta de ar enquanto repousava? | 1 | 2 | 3 | 4 | |
4. Sentiu falta de ar enquanto andava? | 1 | 2 | 3 | 4 | |
5. Sentiu falta de ar enquanto subia escadas (se subisse)? | 1 | 2 | 3 | 4 | |
6. Sentiu sua boca ou língua doloridas? | 1 | 2 | 3 | 4 | |
7. Sentiu dificuldade ao engolir? | 1 | 2 | 3 | 4 | |
8. Sentiu dormência (formigueiro) nas mãos ou nos pés? | 1 | 2 | 3 | 4 | |
9. Teve queda de cabelo? | 1 | 2 | 3 | 4 | |
10. Sentiu dores no peito? | 1 | 2 | 3 | 4 | |
11. Sentiu dores no braço ou no ombro? | 1 | 2 | 3 | 4 | |
12. Sentiu dores em outras partes de seu corpo? | 1 | 2 | 3 | 4 | |
Em caso afirmativo, onde:____________ | |||||
13. Tomou algum medicamento para passar a dor? | |||||
1 Não | 2 Sim | ||||
Em caso afirmativo, até que ponto a dor melhorou? | 1 | 2 | 3 | 4 | |
Rights and permissions
About this article
Cite this article
Brabo, E.P., Paschoal, M.E.M., Biasoli, I. et al. Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res 15, 1519–1524 (2006). https://doi.org/10.1007/s11136-006-0009-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-006-0009-9